Erythrocyte sedimentation rate in diabetic and non-diabetic patients of cardiovascular disease
The pervasiveness of global endemic of type II diabetes, driven by population development, increasing obesity, urbanization, and other additional unidentified factors may be crumpled in the next 20yrs. The purpose of this study was to determine the correlation of ESR in diabetic and non-diabetic patients of cardiovascular diseases. It is a co-relational study conducted at KRL hospital Islamabad from February 2018 to September 2018. The study population compromised a total of 180 cases aged 45 to 50 years were taken, in which 60 cases of CVD with DM, 60 cases of CVD without DM and 60 normal healthy population were taken. All patients and controls gave written informed consent. All subjects went through a general physical examination, and a questionnaire was used to collect the records about demographics and past medical history and existing use of medications. In the presented study, Pearson's Correlation between ESR of healthy and ESR of CVD without DM shows a weak correlation between these two variables i.e., 0.127 with a p-value of 0.503. We also establish that there is a direct intermediate relationship between ESR of healthy and ESR of CVD with DM. High level of ESR in CVD patients might indicate the prognosis of DM. To confirm this further researches and studies must be conducted in this area
There is no Figure or data content available for this article
2. Swami, S.S., et al., Hypertension and diabetes in India: a review. Int J Clin Biochem Res, 2015. 2(March): p. 54-8.
3. Joshi, S.R. and R.M. Parikh, India; The Diabetes Capital of the World: Now heading Towards Hypertension. Journal-Association Of Physicians Of India, 2007. 55(Y): p. 323.
4. Shera, A., F. Jawad, and A. Maqsood, Prevalence of diabetes in Pakistan. Diabetes research and clinical practice, 2007. 76(2): p. 219-222.
5. Cosentino, F. and G. Egidy Assenza, Diabetes and inflammation. Herz, 2004. 29(8): p. 749-759.
6. Sharma, R., et al., The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology, 2000. 36(2): p. 523-528.
7. Bozkurt, B., D.L. Mann, and A. Deswal, Biomarkers of inflammation in heart failure. Heart failure reviews, 2010. 15(4): p. 331-341.
8. Maradit-Kremers, H., et al., Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Annals of the rheumatic diseases, 2007. 66(1): p. 76-80.
9. Deswal, A., et al., Cytokines and cytokine receptors in advanced heart failure an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation, 2001. 103(16): p. 2055-2059.
10. Willerson, J.T. and P.M. Ridker, Inflammation as a cardiovascular risk factor. Circulation, 2004. 109(21 suppl 1): p. II-2-II-10.
11. Danesh, J., et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New England Journal of Medicine, 2004. 350(14): p. 1387-1397.
12. Cesari, M., et al., Inflammatory markers and onset of cardiovascular events results from the Health ABC Study. Circulation, 2003. 108(19): p. 2317-2322.
13. Sudha, R., et al., SERUM SIALIC ACID IN RELATION TO ERYTHROCYTE SEDIMENTATION RATE AND HbA OF TYPE 2 DIABETIC PATIENTS.
14. Music, M., et al., Analysis of Inflammatory parameters in Diabetes Mellitus Type 2 patients with or without Metabolic Syndrome. Materia Socio-Medica, 2010. 22(2): p. 64.
15. Ingelsson, E., et al., Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure. Journal of the American College of Cardiology, 2005. 45(11): p. 1802-1806.
16. Steinvil, A., et al., Determinants of the Erythrocyte Sedimentation Rate in the Era of Microinflammation. American journal of clinical pathology, 2008. 129(3): p. 486-491.
17. Timmer, J., et al., Prognostic value of erythrocyte sedimentation rate in ST segment elevation myocardial infarction: interaction with hyperglycaemia. Journal of internal medicine, 2005. 257(5): p. 423-429.
18. Natali, A., A. L'Abbate, and E. Ferrannini, Erythrocyte sedimentation rate, coronary atherosclerosis, and cardiac mortality. European heart journal, 2003. 24(7): p. 639-648.
19. Gillum, R.F., M.E. Mussolino, and D.M. Makuc, Erythrocyte sedimentation rate and coronary heart disease: the NHANES I Epidemiologic Follow-up Study. Journal of clinical epidemiology, 1995. 48(3): p. 353-361.
How to Cite This
Copyright and Permissions
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.